CYP4F11 Antibody
Description
Target Epitopes and Reactivity
-
Antigen Regions: Common epitopes include amino acid residues 51–100 (internal region) and 38–524 (full-length protein) .
-
Cross-Reactivity: Demonstrated specificity for human and mouse CYP4F11, with predicted reactivity in chimpanzee, gorilla, and rat .
Applications in Biomedical Research
CYP4F11 antibodies are widely used to explore the enzyme’s role in health and disease:
Expression Profiling
-
Normal Tissues: Detected in liver, kidney, heart, brain, and skeletal muscle .
-
Cancer: Overexpressed in ovarian and colorectal tumors, with reduced expression in metastases .
-
Subcellular Localization: Cytoplasmic staining in normal colonic epithelium, primary tumors, and lymph node metastases .
Functional Studies
-
Drug Metabolism: Used to validate CYP4F11’s activity in metabolizing erythromycin, imipramine, and chlorpromazine .
-
Eicosanoid Regulation: Critical for detecting CYP4F11’s omega-hydroxylation of leukotriene B4 (LTB4) and 20-HETE, which regulate inflammation and vascular function .
Disease Mechanisms
-
Malaria: Identifies 4-hydroxynonenal (4-HNE)-modified CYP4F11 in monocytes, linking enzyme inhibition to immune dysfunction .
-
Hypertension: Analyzes genetic variants (e.g., rs1060463) associated with altered vitamin K metabolism and stroke risk .
Clinical Relevance in Cancer
Genetic and Proteomic Insights
-
Haplotype Mapping: 20 unique haplotypes spanning CYP4F2 and CYP4F11 loci influence enzyme abundance and activity .
-
Protein Quantification: CYP4F2 dominates the hepatic CYP4F pool (61–83% abundance), except in CYP4F23 carriers .
Validation Data
-
Western Blot: Detects a single band at ~57 kDa in human liver microsomes .
-
IHC Optimization: Antigen retrieval with TE buffer (pH 9.0) enhances staining in hepatocirrhosis tissues .
-
Functional Assays: Confirms inhibition of CYP4F11 by 4-HNE in malaria models .
Supplier Comparison
| Supplier | Catalog No. | Target Region | Applications |
|---|---|---|---|
| Proteintech | 12286-1-AP | Full-length (38–524) | WB, IHC, IF/ICC, ChIP |
| Antibodies-Online | ABIN203436 | AA 51–100 | WB, ELISA |
Future Directions
Product Specs
Target Background
The CYP4F11 antibody targets cytochrome P450 4F11, a monooxygenase enzyme involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins). Its mechanism involves the utilization of molecular oxygen to insert one oxygen atom into a substrate while reducing the second to a water molecule. This process requires two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). CYP4F11 exhibits high efficiency in catalyzing the omega-oxidation (oxidation of the terminal carbon) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, contributing to the biosynthesis of long-chain 3-hydroxydicarboxylic acids. Furthermore, it omega-hydroxylates and inactivates phylloquinone (vitamin K1) and menaquinone-4 (MK-4, a vitamin K2 form), both crucial cofactors in blood coagulation. While exhibiting lower efficiency, CYP4F11 also metabolizes fatty acids including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE). Additionally, it catalyzes N- and O-demethylation reactions of various drugs, including erythromycin, benzphetamine, ethylmorphine, chlorpromazine, imipramine, and verapamil.
- Studies indicate that CYP4F11 substrate metabolism may be reduced in individuals with the CYP4F11 D315N genetic variant. Those with the common D446N variant appear to exhibit 20-HETE synthesis comparable to individuals expressing wild-type CYP4F11. PMID: 28347661
- Menaquinone-4 omega-hydroxylation activities in microsomes correlated with the CYP4F2 V433M genotype, but not the CYP4F11 D446N genotype. PMID: 24138531
- The CYP4F11 gene is positively regulated by several signaling pathways in HaCaT keratinocytes, including retinoid X receptor and JNK signaling pathways. PMID: 19812349
- Hepatic conversion of 3-hydroxystearate and 3-hydroxypalmitate to omega-hydroxylated 3-OHDCA precursors is mediated by CYP4F11, with minor contribution from CYP4F2. CYP4F3b, CYP4F12, and CYP4A11 showed negligible activity in this process. PMID: 18065749
